Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 5/20 | 1.00 |
| ▸ | PLOD3 | O60568 | 3/20 | 1.00 |
| ▸ | PLOD1 | Q02809 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | F7 | P08709 | 1/20 | 0.49 |
| ▸ | F3 | P13726 | 1/20 | 0.49 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.49 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10320930 | 0.84 | PLOD2 (0.89) | PLOD2PLOD3PLOD1ALDH1A1HDAC1 | |
| SCHEMBL29554726 | 0.84 | PLOD2 (0.89) | PLOD2PLOD3PLOD1ALDH1A1HDAC1 | |
| SCHEMBL15395343 | 0.80 | PLOD2 (0.69) | PLOD2PLOD3PLOD1ALDH1A1L3MBTL1 | |
| SCHEMBL8521979 | 0.79 | PLOD2 (0.66) | PLOD2PLOD3PLOD1ALDH1A1HDAC1 | |
| SCHEMBL4625207 | 0.79 | PLOD2 (1.00) | PLOD2PLOD3PLOD1ALDH1A1HDAC1 | |
| SCHEMBL2694778 | 0.79 | PLOD2 (0.79) | PLOD2PLOD3PLOD1ALDH1A1HDAC1 | |
| SCHEMBL30440488 | 0.79 | PLOD2 (1.00) | PLOD2PLOD3PLOD1ALDH1A1HDAC1 | |
| SCHEMBL1924749 | 0.79 | PLOD2 (1.00) | PLOD2PLOD3PLOD1ALDH1A1GAA | |
| SCHEMBL523476 | 0.78 | PLOD2 (0.69) | PLOD2PLOD3PLOD1ALDH1A1HDAC1 | |
| SCHEMBL21408730 | 0.78 | PLOD2 (0.67) | PLOD2PLOD3PLOD1ALDH1A1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883577-B1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | UNIV CASE WESTERN RESERVE (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2025-10-02 | — | — | US | disclosed |
| US-12336982-B2 | Compositions and methods of modulating short-chain dehydrogenase activity | RODEO THERAPEUTICS CORPORATION (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250161277-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-22 | — | — | US | disclosed |
| EP-4526293-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | Repare Therapeutics Inc. (CA) | 2025-03-26 | — | — | EP | disclosed |
| WO-2024215863-A2 | INHIBITING MONOACYLGLYCEROL LIPASE (MAGL) | PSY THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2023220831-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-23 | — | — | WO | disclosed |
| EP-3722379-B1 | INK COMPOSITION AND PRINTED MATTER | DAINIPPON PRINTING CO LTD (JP) | 2023-10-11 | — | — | EP | disclosed |
| EP-3783072-B1 | INK COMPOSITION, PRINTED PRODUCT, AND AUTHENTICITY DETERMINATION METHOD | DAINIPPON PRINTING CO LTD (JP) | 2023-04-12 | — | — | EP | disclosed |
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | RODEO THERAPEUTICS CORPORATION | 2023-02-09 | — | — | US | disclosed |
| EP-1960367-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| US-20080051421-A1 | Pyrazolo-pyridine | WICHMANN JUERGEN | 2008-02-28 | — | — | US | disclosed |
| US-7329662-B2 | Pyrazolo-pyridine | HOFFMANN-LA ROCHE INC. (US) | 2008-02-12 | — | — | US | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007067836-A2 | SUBSTITUTED PYRAZOLE COMPOUNDS USEFUL AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| EP-1670801-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
| WO-2005040171-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
| US-4708494-A | Methods and devices for the optical measurement of temperature with luminescent materials | KLEINERMAN MARCOS (US) | 1987-11-24 | — | — | US | disclosed |
| US-4444774-A | TRANQUILIZERS | AMERICAN CYANAMID COMPANY (US) | 1984-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161277-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | PLOD2 380/4885PLOD3 613/4885PLOD1 428/4885 |
| US-20250304537-A1 | HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK2A1 | PLOD2 4720/4885PLOD3 3997/4885PLOD1 4412/4885 |
| US-12336982-B2 | Compositions and methods of modulating short-chain dehydrogenase activity | HPGD, GCDH, HPGDS | PLOD2 380/4885PLOD3 613/4885PLOD1 428/4885 |
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | PLOD2 3738/4885PLOD3 3474/4885PLOD1 3848/4885 |
| US-20230039604-A1 | COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY | HPGD, GCDH, HPGDS | PLOD2 380/4885PLOD3 613/4885PLOD1 428/4885 |
| US-20080051421-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | PLOD2 3738/4885PLOD3 3474/4885PLOD1 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.